Trade Aquestive Therapeutics, Inc. - AQST CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Spread | 0.0196 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Aquestive Therapeutics Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 4.3452 |
| Open* | 4.3452 |
| 1-Year Change* | 217.59% |
| Day's Range* | 4.2652 - 4.4252 |
| 52 wk Range | 0.72-2.81 |
| Average Volume (10 days) | 1.16M |
| Average Volume (3 months) | 10.61M |
| Market Cap | 165.58M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 66.77M |
| Revenue | 48.06M |
| EPS | -0.25 |
| Dividend (Yield %) | N/A |
| Beta | 2.76 |
| Next Earnings Date | Mar 5, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 22, 2024 | 4.3452 | 0.2300 | 5.59% | 4.1152 | 4.3752 | 3.9952 |
| Apr 19, 2024 | 4.0852 | -0.2600 | -5.98% | 4.3452 | 4.5152 | 4.0452 |
| Apr 18, 2024 | 4.4852 | 0.5300 | 13.40% | 3.9552 | 4.5052 | 3.9052 |
| Apr 17, 2024 | 3.9052 | 0.0300 | 0.77% | 3.8752 | 4.0352 | 3.8152 |
| Apr 16, 2024 | 3.8352 | 0.0500 | 1.32% | 3.7852 | 3.8752 | 3.7052 |
| Apr 15, 2024 | 3.9252 | -0.1000 | -2.48% | 4.0252 | 4.0452 | 3.7952 |
| Apr 12, 2024 | 3.8952 | -0.1600 | -3.95% | 4.0552 | 4.0852 | 3.7552 |
| Apr 11, 2024 | 4.0852 | -0.1300 | -3.08% | 4.2152 | 4.3252 | 4.0652 |
| Apr 10, 2024 | 4.0452 | 0.1100 | 2.80% | 3.9352 | 4.1352 | 3.9352 |
| Apr 9, 2024 | 4.0752 | 0.0600 | 1.49% | 4.0152 | 4.1552 | 3.9052 |
| Apr 8, 2024 | 4.0652 | 0.0800 | 2.01% | 3.9852 | 4.1352 | 3.9352 |
| Apr 5, 2024 | 4.0752 | -0.0600 | -1.45% | 4.1352 | 4.2852 | 3.9652 |
| Apr 4, 2024 | 4.1452 | -0.0500 | -1.19% | 4.1952 | 4.3152 | 3.8952 |
| Apr 3, 2024 | 4.3652 | 0.2800 | 6.85% | 4.0852 | 4.4852 | 4.0452 |
| Apr 2, 2024 | 4.1452 | 0.1400 | 3.50% | 4.0052 | 4.2352 | 4.0052 |
| Apr 1, 2024 | 4.1152 | -0.1700 | -3.97% | 4.2852 | 4.3452 | 4.0452 |
| Mar 28, 2024 | 4.2352 | 0.0300 | 0.71% | 4.2052 | 4.4552 | 4.1652 |
| Mar 27, 2024 | 4.0652 | -0.0500 | -1.22% | 4.1152 | 4.1952 | 3.9752 |
| Mar 26, 2024 | 4.0452 | -0.0800 | -1.94% | 4.1252 | 4.3152 | 4.0152 |
| Mar 25, 2024 | 4.1352 | -0.2400 | -5.49% | 4.3752 | 4.4852 | 4.0052 |
Aquestive Therapeutics, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Tuesday, April 30, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q1 2024 Aquestive Therapeutics Inc Earnings Release Q1 2024 Aquestive Therapeutics Inc Earnings ReleaseForecast -Previous - |
| Thursday, June 20, 2024 | ||
| Time (UTC) 13:30 | Country US
| Event Aquestive Therapeutics Inc Annual Shareholders Meeting Aquestive Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 5, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q2 2024 Aquestive Therapeutics Inc Earnings Release Q2 2024 Aquestive Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 47.68 | 50.832 | 45.849 | 52.609 | 67.43 |
| Revenue | 47.68 | 50.832 | 45.849 | 52.609 | 67.43 |
| Cost of Revenue, Total | 19.386 | 14.989 | 12.964 | 20.361 | 20.988 |
| Gross Profit | 28.294 | 35.843 | 32.885 | 32.248 | 46.442 |
| Total Operating Expense | 89.746 | 99.333 | 88.742 | 110.173 | 116.364 |
| Selling/General/Admin. Expenses, Total | 52.879 | 53.475 | 55.892 | 64.342 | 72.264 |
| Research & Development | 17.481 | 17.047 | 19.886 | 20.574 | 23.112 |
| Unusual Expense (Income) | 0 | 13.822 | 0 | 4.896 | |
| Operating Income | -42.066 | -48.501 | -42.893 | -57.564 | -48.934 |
| Interest Income (Expense), Net Non-Operating | -12.344 | -22.038 | -12.89 | -8.682 | -12.437 |
| Other, Net | -0.005 | ||||
| Net Income Before Taxes | -54.41 | -70.539 | -55.783 | -66.246 | -61.376 |
| Net Income After Taxes | -54.41 | -70.539 | -55.783 | -66.246 | -61.376 |
| Net Income Before Extra. Items | -54.41 | -70.539 | -55.783 | -66.246 | -61.376 |
| Net Income | -54.41 | -70.539 | -55.783 | -66.246 | -61.376 |
| Total Adjustments to Net Income | 0 | ||||
| Income Available to Common Excl. Extra. Items | -54.41 | -70.539 | -55.783 | -66.246 | -61.376 |
| Income Available to Common Incl. Extra. Items | -54.41 | -70.539 | -55.783 | -66.246 | -61.376 |
| Diluted Net Income | -54.41 | -70.539 | -55.783 | -66.246 | -61.376 |
| Diluted Weighted Average Shares | 48.7344 | 38.0777 | 33.6511 | 25.3561 | 20.7255 |
| Diluted EPS Excluding Extraordinary Items | -1.11646 | -1.8525 | -1.65769 | -2.61263 | -2.96137 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -1.11646 | -1.48951 | -1.65769 | -2.41954 | -2.96137 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 13.241 | 11.134 | 10.682 | 11.463 | 13.265 |
| Revenue | 13.241 | 11.134 | 10.682 | 11.463 | 13.265 |
| Cost of Revenue, Total | 6.617 | 4.737 | 5.305 | 4.625 | 5.242 |
| Gross Profit | 6.624 | 6.397 | 5.377 | 6.838 | 8.023 |
| Total Operating Expense | 17.45 | 16.092 | 21.395 | 20.316 | 26.027 |
| Selling/General/Admin. Expenses, Total | 7.36 | 7.455 | 11.812 | 12.459 | 15.587 |
| Research & Development | 3.473 | 3.547 | 4.278 | 3.232 | 5.198 |
| Operating Income | -4.209 | -4.958 | -10.713 | -8.853 | -12.762 |
| Interest Income (Expense), Net Non-Operating | -1.299 | 13.026 | -1.639 | -3.683 | -3.54 |
| Net Income Before Taxes | -5.508 | 8.068 | -12.352 | -12.536 | -16.302 |
| Net Income After Taxes | -5.792 | 8.068 | -12.352 | -12.536 | -16.302 |
| Net Income Before Extra. Items | -5.792 | 8.068 | -12.352 | -12.536 | -16.302 |
| Net Income | -5.792 | 8.068 | -12.352 | -12.536 | -16.302 |
| Income Available to Common Excl. Extra. Items | -5.792 | 8.068 | -12.352 | -12.536 | -16.302 |
| Income Available to Common Incl. Extra. Items | -5.792 | 8.068 | -12.352 | -12.536 | -16.302 |
| Diluted Net Income | -5.792 | 8.068 | -12.352 | -12.536 | -16.302 |
| Diluted Weighted Average Shares | 57.3509 | 73.7929 | 54.4529 | 53.4249 | 45.4625 |
| Diluted EPS Excluding Extraordinary Items | -0.10099 | 0.10933 | -0.22684 | -0.23465 | -0.35858 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.10099 | 0.11412 | -0.22684 | -0.23465 | -0.35858 |
| Unusual Expense (Income) | 0 | 0.353 | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 39.888 | 47.259 | 44.625 | 68.314 | 74.201 |
| Cash and Short Term Investments | 27.273 | 28.024 | 31.807 | 49.326 | 60.599 |
| Cash & Equivalents | 27.273 | 28.024 | 31.807 | 49.326 | 60.599 |
| Total Receivables, Net | 4.704 | 12.12 | 6.955 | 13.13 | 6.481 |
| Accounts Receivable - Trade, Net | 4.704 | 12.12 | 6.955 | 13.13 | 6.448 |
| Total Inventory | 5.78 | 4.038 | 2.461 | 2.859 | 5.441 |
| Prepaid Expenses | 2.131 | 3.077 | 3.402 | 2.999 | 1.68 |
| Other Current Assets, Total | |||||
| Total Assets | 57.07 | 61.993 | 62.884 | 78.479 | 86.851 |
| Property/Plant/Equipment, Total - Net | 9.296 | 7.78 | 10.321 | 9.726 | 12.207 |
| Property/Plant/Equipment, Total - Gross | 51.259 | 47.64 | 51.199 | 47.77 | 47.398 |
| Accumulated Depreciation, Total | -41.963 | -39.86 | -40.878 | -38.044 | -35.191 |
| Intangibles, Net | 1.435 | 0.051 | 0.102 | 0.439 | 0.204 |
| Other Long Term Assets, Total | 1.451 | 0.903 | 0.836 | 0.239 | |
| Total Current Liabilities | 39.528 | 21.964 | 21.104 | 18.555 | 32.952 |
| Accounts Payable | 9.946 | 8.314 | 7.089 | 12.274 | 20.436 |
| Accrued Expenses | 8.222 | 9.635 | 9.297 | 5.232 | 6.988 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 2.66 | 1.99 | 2.143 | 1.049 | 0.928 |
| Total Liabilities | 175.624 | 144.127 | 111.381 | 84.601 | 76.771 |
| Total Long Term Debt | 33.448 | 51.551 | 34.329 | 60.338 | 42.603 |
| Long Term Debt | 33.448 | 51.551 | 34.329 | 60.338 | 42.603 |
| Other Liabilities, Total | 102.648 | 70.612 | 55.948 | 5.708 | 1.216 |
| Total Equity | -118.554 | -82.134 | -48.497 | -6.122 | 10.08 |
| Redeemable Preferred Stock | 0 | ||||
| Common Stock | 0.055 | 0.041 | 0.035 | 0.034 | 0.025 |
| Additional Paid-In Capital | 192.598 | 174.621 | 137.725 | 124.318 | 71.431 |
| Retained Earnings (Accumulated Deficit) | -311.207 | -256.796 | -186.257 | -130.474 | -61.376 |
| Total Liabilities & Shareholders’ Equity | 57.07 | 61.993 | 62.884 | 78.479 | 86.851 |
| Total Common Shares Outstanding | 54.8277 | 41.2287 | 34.5692 | 33.5629 | 24.9573 |
| Current Port. of LT Debt/Capital Leases | 18.7 | 2.025 | 2.575 | 0 | 4.6 |
| Note Receivable - Long Term | 5 | 6 | 7 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 42.457 | 39.788 | 43.706 | 39.888 | 38.087 |
| Cash and Short Term Investments | 24.917 | 22.436 | 26.882 | 27.273 | 18.649 |
| Cash & Equivalents | 24.917 | 22.436 | 26.882 | 27.273 | 18.649 |
| Total Receivables, Net | 8.55 | 10.101 | 7.551 | 4.704 | 10.737 |
| Accounts Receivable - Trade, Net | 8.55 | 10.101 | 7.551 | 4.704 | 10.737 |
| Total Inventory | 7.079 | 5.95 | 6.981 | 5.78 | 6.725 |
| Prepaid Expenses | 1.911 | 1.301 | 2.292 | 2.131 | 1.976 |
| Total Assets | 59.448 | 56.994 | 61.285 | 57.07 | 51.845 |
| Property/Plant/Equipment, Total - Net | 10.22 | 10.38 | 9.698 | 9.296 | 6.378 |
| Property/Plant/Equipment, Total - Gross | 52.932 | 52.879 | 51.945 | 51.259 | 48.007 |
| Accumulated Depreciation, Total | -42.712 | -42.499 | -42.247 | -41.963 | -41.629 |
| Intangibles, Net | 1.317 | 1.357 | 1.396 | 1.435 | 1.487 |
| Note Receivable - Long Term | 4 | 4 | 5 | 5 | 5 |
| Other Long Term Assets, Total | 1.454 | 1.469 | 1.485 | 1.451 | 0.893 |
| Total Current Liabilities | 24.057 | 38.653 | 40.383 | 39.528 | 36.56 |
| Accounts Payable | 9.994 | 10.689 | 12.44 | 9.946 | 11.072 |
| Accrued Expenses | 5.835 | 4.61 | 4.836 | 8.222 | 8.579 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 4.606 | 18.362 | 17.195 | 18.7 | 14.225 |
| Other Current Liabilities, Total | 3.622 | 4.992 | 5.912 | 2.66 | 2.684 |
| Total Liabilities | 162.375 | 163.645 | 170.52 | 175.624 | 159.664 |
| Total Long Term Debt | 34.555 | 20.801 | 25.196 | 33.448 | 38.675 |
| Long Term Debt | 34.555 | 20.801 | 25.196 | 33.448 | 38.675 |
| Other Liabilities, Total | 103.763 | 104.191 | 104.941 | 102.648 | 84.429 |
| Total Equity | -102.927 | -106.651 | -109.235 | -118.554 | -107.819 |
| Common Stock | 0.067 | 0.062 | 0.056 | 0.055 | 0.054 |
| Additional Paid-In Capital | 207.972 | 202.218 | 193.848 | 192.598 | 190.982 |
| Retained Earnings (Accumulated Deficit) | -310.966 | -308.931 | -303.139 | -311.207 | -298.855 |
| Total Liabilities & Shareholders’ Equity | 59.448 | 56.994 | 61.285 | 57.07 | 51.845 |
| Total Common Shares Outstanding | 66.7408 | 61.616 | 55.9224 | 54.8277 | 53.8521 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -54.41 | -70.539 | -55.783 | -66.246 | -61.376 |
| Cash From Operating Activities | -9.789 | -32.979 | -45.459 | -60.21 | -12.991 |
| Cash From Operating Activities | 2.387 | 2.964 | 3.443 | 2.905 | 3.186 |
| Amortization | 0.05 | ||||
| Non-Cash Items | 10.227 | 36.326 | 11.294 | 14.255 | 37.151 |
| Cash Interest Paid | 6.436 | 6.438 | 8.491 | 7.34 | 6.049 |
| Changes in Working Capital | 32.007 | -1.73 | -4.413 | -11.124 | 7.998 |
| Cash From Investing Activities | -2.524 | -0.913 | -0.517 | -0.663 | -1.824 |
| Capital Expenditures | -2.524 | -0.913 | -0.517 | -0.663 | -1.824 |
| Other Investing Cash Flow Items, Total | |||||
| Cash From Financing Activities | 11.562 | 30.109 | 28.457 | 49.6 | 58.035 |
| Financing Cash Flow Items | -0.003 | -0.014 | -3.008 | -6.773 | -10.795 |
| Issuance (Retirement) of Stock, Net | 13.59 | 30.123 | 6.215 | 39.317 | 68.83 |
| Issuance (Retirement) of Debt, Net | -2.025 | 0 | 25.25 | 17.056 | 0 |
| Net Change in Cash | -0.751 | -3.783 | -17.519 | -11.273 | 43.22 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 8.068 | -54.41 | -42.058 | -29.522 | -13.22 |
| Cash From Operating Activities | 8.816 | -9.789 | -18.235 | -21.044 | -14.482 |
| Cash From Operating Activities | 0.325 | 2.387 | 1.99 | 1.394 | 0.727 |
| Non-Cash Items | 0.14 | 10.227 | 9.567 | 6.802 | 2.689 |
| Cash Interest Paid | 1.466 | 6.436 | 1.609 | 1.609 | 1.609 |
| Changes in Working Capital | 0.283 | 32.007 | 12.266 | 0.282 | -4.678 |
| Cash From Investing Activities | -0.002 | -2.524 | -2.498 | -0.781 | -0.104 |
| Capital Expenditures | -0.002 | -2.524 | -2.498 | -0.781 | -0.104 |
| Cash From Financing Activities | -9.205 | 11.562 | 11.358 | 11.496 | 1.298 |
| Financing Cash Flow Items | -0.008 | -0.003 | -0.003 | 0 | |
| Issuance (Retirement) of Stock, Net | 0.916 | 13.59 | 12.711 | 12.171 | 1.298 |
| Net Change in Cash | -0.391 | -0.751 | -9.375 | -10.329 | -13.288 |
| Issuance (Retirement) of Debt, Net | -10.113 | -2.025 | -1.35 | -0.675 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Aquestive Therapeutics, Inc. Company profile
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing differentiated products which leverage PharmFilm. Its late-stage product pipeline focused on the treatment of central nervous system (CNS), diseases and an earlier stage pipeline including treatment of anaphylaxis. Its commercialized licensed product is Suboxone, a sublingual film formulation of buprenorphine and naloxone, for the treatment of opioid dependence. Its CNS portfolio focused on epilepsy includes, Sympazan an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut syndrome (LGS). Its portfolio also includes Suboxone a sublingual film formulation of buprenorphine and naloxone, respectively an opioid agonist and antagonist for the treatment of opioid dependence.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Aquestive Therapeutics Inc revenues increased 11% to $50.8M. Net loss increased 26% to $70.5M. Revenues reflect Ex-United States segment increase of 63% to $8M, United States segment increase of 5% to $42.9M. Higher net loss reflects Interest expense related to the sale increase from $2M to $12.4M (expense), Stock-based Compensation in R&D increase of 21% to $881K (expense).
Equity composition
Common Stock $.01 Par, Shares auth. and o/s after the offering: 100M auth., 15,029,412 issd. Insiders own approx. 1% (after the IPO). IPO: TBA. 4M shares Offered. 03/08, IPO withdrawn.
| Industry: | Pharmaceuticals (NEC) |
30 Technology Dr
WARREN
NEW JERSEY 07059-5166
US
Income Statement
- Annual
- Quarterly
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com